Bolaji O O, Sadare I O, Babalola C P, Ogunbona F A
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.
Eur J Clin Pharmacol. 2002 Nov;58(8):543-5. doi: 10.1007/s00228-002-0509-7. Epub 2002 Sep 24.
The genetic polymorphic metabolic oxidation of proguanil was investigated in 126 healthy, unrelated Nigerian subjects as an indication of the phenotypic status of CYP2C19 in Nigerians.
The proguanil oxidation capacity was determined using the 8-h urinary metabolic ratio of the parent drug and its metabolite (cycloguanil) after a single oral dose of 200 mg proguanil.
The frequency distribution of the proguanil metabolic ratio ranged from 0.01 to 39.64 with a median of 1.38 in the 126 Nigerians. On the basis of the antimode value of 10 for the proguanil/cycloguanil ratio, the prevalence of poor metabolisers in this Nigerian population was estimated to be 4.8% (6 of 126), which is very similar to that of S-mephenytoin (4.3%) found in a previous study in Nigerians. The data also demonstrated enormous inter-individual differences in the urinary proguanil/cycloguanil ratios with poor metabolisers excreting, on average, only about 8% of the quantity of cycloguanil excreted by extensive metabolisers.
The incidence of phenotypically poor metabolisers of proguanil in this Nigerian population is similar to those reported for Caucasian and other African populations but is much lower than those reported for Orientals. The study further supports previous studies that proguanil can be used as an alternative probe to phenotype for CYP2C19 activity.
在126名健康、无亲缘关系的尼日利亚受试者中研究了氯胍的遗传多态性代谢氧化情况,以此作为尼日利亚人CYP2C19表型状态的一个指标。
单次口服200mg氯胍后,通过母体药物及其代谢物(环氯胍)的8小时尿代谢率来测定氯胍的氧化能力。
在126名尼日利亚人中,氯胍代谢率的频率分布范围为0.01至39.64,中位数为1.38。根据氯胍/环氯胍比值的反众数10,估计该尼日利亚人群中代谢缓慢者的患病率为4.8%(126人中6人),这与之前在尼日利亚人研究中发现的S-美芬妥因的患病率(4.3%)非常相似。数据还显示尿氯胍/环氯胍比值存在巨大的个体差异,代谢缓慢者排出的环氯胍量平均仅约为代谢快速者排出量的8%。
该尼日利亚人群中氯胍表型代谢缓慢者的发生率与白种人和其他非洲人群报道的相似,但远低于东方人群报道的发生率。该研究进一步支持了之前的研究,即氯胍可作为CYP2C19活性表型分析的替代探针。